Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.15
AKRX's Cash to Debt is ranked lower than
53% of the 801 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. AKRX: 0.15 )
AKRX' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: 0.15

Equity to Asset 0.24
AKRX's Equity to Asset is ranked lower than
53% of the 750 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. AKRX: 0.24 )
AKRX' s 10-Year Equity to Asset Range
Min: 0.1   Max: 0.91
Current: 0.24

0.1
0.91
Interest Coverage 10.10
AKRX's Interest Coverage is ranked higher than
55% of the 484 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 76.05 vs. AKRX: 10.10 )
AKRX' s 10-Year Interest Coverage Range
Min: 2.47   Max: 9999.99
Current: 10.1

2.47
9999.99
F-Score: 3
Z-Score: 3.34
M-Score: -1.36
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 21.12
AKRX's Operating margin (%) is ranked higher than
92% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.55 vs. AKRX: 21.12 )
AKRX' s 10-Year Operating margin (%) Range
Min: -50.73   Max: 27.5
Current: 21.12

-50.73
27.5
Net-margin (%) 11.57
AKRX's Net-margin (%) is ranked higher than
83% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.99 vs. AKRX: 11.57 )
AKRX' s 10-Year Net-margin (%) Range
Min: -36.46   Max: 31.41
Current: 11.57

-36.46
31.41
ROE (%) 18.25
AKRX's ROE (%) is ranked higher than
92% of the 796 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. AKRX: 18.25 )
AKRX' s 10-Year ROE (%) Range
Min: -108.38   Max: 35.12
Current: 18.25

-108.38
35.12
ROA (%) 8.09
AKRX's ROA (%) is ranked higher than
74% of the 809 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.01 vs. AKRX: 8.09 )
AKRX' s 10-Year ROA (%) Range
Min: -33.5   Max: 24.27
Current: 8.09

-33.5
24.27
ROC (Joel Greenblatt) (%) 44.58
AKRX's ROC (Joel Greenblatt) (%) is ranked higher than
86% of the 805 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.22 vs. AKRX: 44.58 )
AKRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -41.62   Max: 56.21
Current: 44.58

-41.62
56.21
Revenue Growth (%) 47.50
AKRX's Revenue Growth (%) is ranked higher than
96% of the 670 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. AKRX: 47.50 )
AKRX' s 10-Year Revenue Growth (%) Range
Min: -37   Max: 47.5
Current: 47.5

-37
47.5
EBITDA Growth (%) 49.20
AKRX's EBITDA Growth (%) is ranked higher than
95% of the 639 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. AKRX: 49.20 )
AKRX' s 10-Year EBITDA Growth (%) Range
Min: -67.1   Max: 171.4
Current: 49.2

-67.1
171.4
EPS Growth (%) 27.90
AKRX's EPS Growth (%) is ranked higher than
87% of the 624 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. AKRX: 27.90 )
AKRX' s 10-Year EPS Growth (%) Range
Min: -50.4   Max: 93.1
Current: 27.9

-50.4
93.1
» AKRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

AKRX Guru Trades in Q3 2013

Joel Greenblatt 30,162 sh (New)
Columbia Wanger 8,268,400 sh (+48.13%)
Steven Cohen Sold Out
» More
Q4 2013

AKRX Guru Trades in Q4 2013

Steven Cohen 28,406 sh (New)
Columbia Wanger 7,263,695 sh (-12.15%)
Joel Greenblatt 17,785 sh (-41.04%)
» More
Q1 2014

AKRX Guru Trades in Q1 2014

Pioneer Investments 297,868 sh (New)
Jim Simons 29,100 sh (New)
Mario Gabelli 15,900 sh (New)
Joel Greenblatt 68,119 sh (+283.01%)
Steven Cohen Sold Out
Columbia Wanger 7,215,700 sh (-0.66%)
» More
Q2 2014

AKRX Guru Trades in Q2 2014

Murray Stahl 26,464 sh (New)
Columbia Wanger 8,123,700 sh (+12.58%)
Jim Simons Sold Out
Pioneer Investments 254,698 sh (-14.49%)
Mario Gabelli 9,950 sh (-37.42%)
Joel Greenblatt 39,285 sh (-42.33%)
» More
» Details

Insider Trades

Latest Guru Trades with AKRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-06-30 Reduce -42.33%0.01%$20.93 - $31.71 $ 36.6240%39285
Mario Gabelli 2014-06-30 Reduce -37.42%$20.93 - $31.71 $ 36.6240%9950
Joel Greenblatt 2014-03-31 Add 283.01%0.02%$21 - $27.81 $ 36.6256%68119
Mario Gabelli 2014-03-31 New Buy$21 - $27.81 $ 36.6256%15900
Joel Greenblatt 2013-12-31 Reduce -41.04%0.01%$19.44 - $25.76 $ 36.6262%17785
Joel Greenblatt 2013-09-30 New Buy0.02%$13.43 - $19.3 $ 36.62127%30162
George Soros 2011-12-31 Sold Out 0.002%$7.45 - $11.48 $ 36.62286%0
George Soros 2011-09-30 New Buy$6.75 - $9.22 $ 36.62368%14900
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 91.10
AKRX's P/E(ttm) is ranked higher than
67% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 42.90 vs. AKRX: 91.10 )
AKRX' s 10-Year P/E(ttm) Range
Min: 13.23   Max: 97.06
Current: 91.1

13.23
97.06
P/B 12.94
AKRX's P/B is ranked higher than
51% of the 828 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.60 vs. AKRX: 12.94 )
AKRX' s 10-Year P/B Range
Min: 1.42   Max: 41.45
Current: 12.94

1.42
41.45
P/S 10.52
AKRX's P/S is ranked higher than
57% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.72 vs. AKRX: 10.52 )
AKRX' s 10-Year P/S Range
Min: 0.43   Max: 12.87
Current: 10.52

0.43
12.87
PFCF 122.07
AKRX's PFCF is ranked higher than
81% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. AKRX: 122.07 )
AKRX' s 10-Year PFCF Range
Min: 39.62   Max: 327
Current: 122.07

39.62
327
EV-to-EBIT 45.04
AKRX's EV-to-EBIT is ranked higher than
71% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 31.14 vs. AKRX: 45.04 )
AKRX' s 10-Year EV-to-EBIT Range
Min: 18.8   Max: 80.4
Current: 45.04

18.8
80.4
Shiller P/E 172.57
AKRX's Shiller P/E is ranked higher than
73% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 121.61 vs. AKRX: 172.57 )
AKRX' s 10-Year Shiller P/E Range
Min: 110.53   Max: 728
Current: 172.57

110.53
728
Current Ratio 3.83
AKRX's Current Ratio is ranked higher than
82% of the 650 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.46 vs. AKRX: 3.83 )
AKRX' s 10-Year Current Ratio Range
Min: 0.21   Max: 9.96
Current: 3.83

0.21
9.96
Quick Ratio 2.78
AKRX's Quick Ratio is ranked higher than
79% of the 650 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. AKRX: 2.78 )
AKRX' s 10-Year Quick Ratio Range
Min: 0.02   Max: 8.49
Current: 2.78

0.02
8.49

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 10.31
AKRX's Price/DCF (Projected) is ranked higher than
75% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.36 vs. AKRX: 10.31 )
AKRX' s 10-Year Price/DCF (Projected) Range
Min: 6.03   Max: 749
Current: 10.31

6.03
749
Price/Median PS Value 1.95
AKRX's Price/Median PS Value is ranked higher than
57% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.25 vs. AKRX: 1.95 )
AKRX' s 10-Year Price/Median PS Value Range
Min: 0.04   Max: 2.24
Current: 1.95

0.04
2.24
Earnings Yield (Greenblatt) 2.20
AKRX's Earnings Yield (Greenblatt) is ranked higher than
59% of the 660 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. AKRX: 2.20 )
AKRX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.2   Max: 5.3
Current: 2.2

1.2
5.3
Forward Rate of Return (Yacktman) 0.10
AKRX's Forward Rate of Return (Yacktman) is ranked higher than
70% of the 664 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.93 vs. AKRX: 0.10 )
AKRX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -3.6   Max: 0.2
Current: 0.1

-3.6
0.2

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:FDA.Germany
Akorn, Inc. is a Louisiana corporation founded in 1971 in Abita Springs, Louisiana. The Company manufactures and markets a full line of diagnostic and therapeutic ophthalmic pharmaceuticals as well as niche hospital drugs and injectable pharmaceuticals. In addition, it has markets and distributes vaccines purchased from outside sources. It operates pharmaceutical manufacturing facilities in Decatur, Illinois and Somerset, New Jersey, an R&D center in Skokie, Illinois and a distribution warehouse in Gurnee, Illinois. Its three operating segments are: ophthalmic; hospital drugs & injectables; contract services. Ophthalmic Segment: It markets a full line of diagnostic and therapeutic ophthalmic pharmaceutical products. Diagnostic products, primarily used in the office setting, include mydriatics and cycloplegics, anesthetics, topical stains, gonioscopic solutions, angiography dyes and others. Therapeutic products, sold primarily to wholesalers, chain drug stores and other national account customers, include antibiotics, steroids, steroid combinations, glaucoma medications, decongestants/antihistamines and anti-edema medications. Non-pharmaceutical products include various artificial tear solutions, preservative-free lubricating ointments and eyelid cleansers. Hospital Drugs & Injectables Segment - it markets a line of niche hospital drug and injectable pharmaceutical products, including antidotes, anti-infectives, and controlled substances for pain management and anesthesia, and other selected pharmaceutical products. These products are predominately sold to hospitals through the wholesale distribution channel. The Company's customers include physicians, optometrists, hospitals, wholesalers, group purchasing organizations, retail pharmacy chains and other pharmaceutical companies. The Company targets products with limited competition due to difficulty in manufacturing and/or the product's market size. Contract Services Segment: It manufactures ophthalmic and injectable pharmaceutical products for third party pharmaceutical customers based on their specifications. Pharmaceutical manufacturers and distributors are subject to extensive regulation by government agencies, including the FDA, the Drug Enforcement Administration (DEA), the Federal Trade Commission (FTC) and other federal, state and local agencies.
» More Articles for AKRX

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Akorn Inc, Under Armour Inc, Anadarko Petroleum Corp, and Graphic Packag Aug 09 2014 
WEEKLY CFO SELLS HIGHLIGHT: AKRX, FIO, OVRL, VRTX Oct 21 2012 
Weekly CFO Sells Highlight: ASGN, COF, AKRX, MCRS, GILD, ROP, PLL Sep 24 2012 
5 Healthcare Picks for 2012 Mar 21 2012 
Weekly CFO Sells Highlight: AN, CATM, AKRX, NNN, FTNT Aug 28 2011 
Akorn Inc. (AKRX) CFO Timothy A Dick buys 3,900 Shares Aug 16 2010 
Akorn Inc. Reports Operating Results (10-Q) May 10 2010 
Akorn Inc. Reports Operating Results (10-Q) Nov 09 2009 
Weekly CFO Buy Highlights: Gigatronics Inc., Akorn Inc., MainSource Financial Group Inc, U.S. Auto P Sep 06 2009 
Akorn Inc. Reports Operating Results (10-Q) Aug 17 2009 

More From Our Partners
Stocks with Upgraded Broker Ratings - Screen of the Week Sep 16 2014 - ZACKS

More From Other Websites
IBD 50 Stocks Setting Up, Including These 5 Medicals Sep 19 2014
Will Drugmaker Akorn Have A Healthy Bounce Up? Sep 18 2014
Is Akorn, Inc. An Easy Buy This Week? Sep 16 2014
AKORN INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Sep 12 2014
5 Top Stocks With Rising Earnings Estimates Sep 12 2014
Akorn In Second Test Of 10-Week Line Sep 11 2014
Stocks Show Modest Losses; Biotechs Pressured Again Sep 11 2014
Salix, Gilead Among 5 Top Medical Leaders To Watch Sep 05 2014
Tight Consolidation Breakouts To Watch Sep 04 2014
Akorn (AKRX): Strong Industry, Solid Earnings Estimate Revisions Sep 03 2014
Stocks Rise As Biotechs Lead; Amazon To Buy Twitch Aug 25 2014
Main Indexes Slip From Highs; Biotechs Show Strength Aug 25 2014
Should You Get Rid of Corium International (CORI) Now? Aug 20 2014
AKORN INC Financials Aug 19 2014
Stock Futures Steer Higher; Dollar General, Akorn Rising Aug 18 2014
AKORN INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition... Aug 15 2014
Perrigo Beats on Q4 Earnings and Sales, Provides Guidance Aug 14 2014
Bull of the Day: Akron Inc (AKRX) Aug 14 2014
AKORN INC Files SEC form 8-K, Other Events Aug 12 2014
Akorn Completes Acquisition of VersaPharm Aug 12 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK